These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6372686)

  • 21. Open study of ceftazidime in serious infections due to multiply-resistant bacteria.
    Pechère JC; Delisle R
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():181-8. PubMed ID: 6352619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.
    Byrne S; Maddison J; Connor P; Doughty I; Dodd M; Jenney M; Webb AK; David TJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():135-43. PubMed ID: 8543489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cephacetrile--a new cephalosporin antibiotic.
    Hodson AH; Holloway WJ
    Int J Clin Pharmacol; 1973 Feb; 7(1):89-94. PubMed ID: 4699390
    [No Abstract]   [Full Text] [Related]  

  • 24. Complicated urinary tract infections treated with ceftazidime and tobramycin: a comparative study.
    Madsen PO; Frimodt-Møller PC
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():77-9. PubMed ID: 6352658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.
    Maslow MJ; Rosenberg A; Pollock AA; Press RA; Silverman D; El-Sadr W; Richmond AS; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():213-7. PubMed ID: 6413486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftazidime in patients with Pseudomonas infections.
    Eron LJ; Park CH; Hixon DL; Goldenberg RI; Poretz DM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():161-9. PubMed ID: 6225762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime treatment in intensive care patients.
    van Dalen R; Muytjens HL; Gimbrère JS
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():189-97. PubMed ID: 6225763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with ceftazidime in cystic fibrosis.
    Dodge J; Zamiri I; Goodchild M; Ingram P
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():325-9. PubMed ID: 6352637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftazidime in severe infections: a Swiss multicentre study.
    Francioli P; Clément M; Geroulanos S; von Graevenitz A; Luthy R; Regamey C; Stalder H; Vogt M; Waldvogel FA
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():139-46. PubMed ID: 6225761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of complicated urinary tract infection caused by Pseudomonas aeruginosa--a comparison of the efficacy of ceftazidime with that of netilmicin.
    Graninger W; Ho I; Francesconi M; Schmidbauer C; Egger T
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():323-4. PubMed ID: 19803008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic effects of cefozopran against experimental mixed urinary tract infection with Enterococcus faecalis and Pseudomonas aeruginosa in mice.
    Tsuchimori N; Yamazaki T; Okonogi K
    J Antimicrob Chemother; 1997 Mar; 39(3):423-5. PubMed ID: 9096195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study on aztreonam, ceftazidime and amikacin in the treatment of complicated urinary tract infections.
    Melekos MD; Skoutelis A; Chryssanthopoulos C; Bassaris HP
    J Chemother; 1991 Dec; 3(6):376-82. PubMed ID: 1819621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa.
    Fantin B; Farinotti R; Thabaut A; Carbon C
    J Antimicrob Chemother; 1994 Mar; 33(3):563-9. PubMed ID: 8040120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftazidime--a new extended-spectrum cephalosporin.
    Gozzard DI; Geddes AM; Farrell ID; Eykyn SJ; Phillips I; Wise R; Brown RM
    Lancet; 1982 May; 1(8282):1152-6. PubMed ID: 6122940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antipseudomonal activities of new cephem antibiotics].
    Ohkoshi M
    Hinyokika Kiyo; 1984 Apr; 30(4):437-48. PubMed ID: 6435413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
    Leigh DA; Emmanuel FX
    J Antimicrob Chemother; 1984 May; 13 Suppl B():85-8. PubMed ID: 6234280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures].
    Blaser J; Bauernfeind A; Vogt M; Lüthy R
    Dtsch Med Wochenschr; 1983 Sep; 108(35):1312-7. PubMed ID: 6411442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapeutic effect of cefluprenam on polymicrobial urinary tract infection associated with Enterococcus faecalis, using the infectious urolithiasis model in rats].
    Satoh M; Takeuchi H; Munakata K; Yoshida O
    Kansenshogaku Zasshi; 1998 Apr; 72(4):371-8. PubMed ID: 9621566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical studies of ceftazidime in the pediatric field].
    Hoshina H; Mikuni K; Ichihashi H
    Jpn J Antibiot; 1984 Mar; 37(3):460-8. PubMed ID: 6376855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime in clinical practice - a summary.
    Norrby SR
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():405-8. PubMed ID: 6352652
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.